From Analysis:
CCL2-CCR2 Axis at NMJ: Mechanism of Selective Motor Neuron Vulnerability in ALS
How does the CCL2-CCR2 chemokine axis at the neuromuscular junction drive selective vulnerability of fast-fatigable motor neurons over slow-resistant motor neurons in ALS, and does blocking CCR2 signalling in myeloid cells reverse NMJ denervation in a cell-type-specific manner in ALS mouse models?
The question is likely underpowered or misleading unless analyses preserve the key strata: CCL2-CCR2, NMJ, ALS, CCR2. Averaging across these strata could convert a causal subpopulation effect into a weak association.
No AI visual card yet
Curated pathway diagram from expert analysis
flowchart TD
A["Single-Cell RNA Sequencing
Motor Neuron State Classification"]
B["Cell-State Stratification Required
Fast vs Slow Twitch vs Intermediate"]
C["CCL2-CCR2 Axis Activation
Pro-Inflammatory State Predominance"]
D["NMJ Denervation Pattern
State-Specific Vulnerability Mapping"]
E["Therapeutic Targeting Precision
State-Specific Intervention Needed"]
F["ALS Precision Medicine
Stratified Treatment Approach"]
A --> B
B --> C
C --> D
D --> E
E --> F
style A fill:#1a237e,stroke:#4fc3f7,color:#4fc3f7
style F fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
Theorist position for analysis f7f8019f-08f6-428b-adff-85e8ea202b60: CCL2-CCR2 Axis at NMJ: Mechanism of Selective Motor Neuron Vulnerability in ALS
Source basis: The CCL2-CCR2 axis drives neuromuscular denervation in amyotrophic lateral sclerosis (Nature Communications, 2025, DOI 10.1038/s41467-025-62351-3). The stored gap context says: Study demonstrated CCL2-CCR2 drives NMJ denervation in ALS but noted that the mechanism of selective fast vs. slow motor neuron vulnerability downstream of this axis was not resolved.
Primary hypothesis: CCL2-CCR2 myeloid signaling as a selective driver of f
Skeptic critique for analysis f7f8019f-08f6-428b-adff-85e8ea202b60: CCL2-CCR2 Axis at NMJ: Mechanism of Selective Motor Neuron Vulnerability in ALS
The source paper motivates the gap, but motivation is not causal evidence. The main threat is that the observed association in The CCL2-CCR2 axis drives neuromuscular denervation in amyotrophic lateral sclerosis could be downstream of disease stage, tissue composition, survival bias, or batch structure. The specific concern here is: CCR2 blockade may reduce inflammation without directly rescuing vulnerable motor-neuron physiology.
The debate shou
Domain expert assessment for analysis f7f8019f-08f6-428b-adff-85e8ea202b60: CCL2-CCR2 Axis at NMJ: Mechanism of Selective Motor Neuron Vulnerability in ALS
The practical path is feasible but should be staged. Stage 1 should reanalyze or collect human data at the needed resolution, preserving pathology, sex/genotype, region, and disease-stage covariates when relevant. Stage 2 should test CCL2-CCR2 myeloid signaling as a selective driver of fast-fatigable motor-neuron denervation in a model where the proximal readout can be measured before overt toxicity. Stage 3 should connect the readout to a
{
"ranked_hypotheses": [
{
"title": "CCL2-CCR2 myeloid signaling as a selective driver of fast-fatigable motor-neuron denervation as proximal driver in CCL2-CCR2 Axis at NMJ: Mechanism of Selective Motor Neuron Vulnerability in ALS",
"description": "CCL2-CCR2 myeloid signaling as a selective driver of fast-fatigable motor-neuron denervation should produce a measurable proximal phenotype before late disease pathology. The decisive test is myeloid-specific CCR2 blockade with fast/slow motor-unit stratification and NMJ integrity measurements.",
"target_gene": "CCL2-CCR2",
No price history recorded yet
No clinical trials data available
No linked papers yet
Freshness score = exp(-age×ln2/5): halves every 5 years. Green >0.6, Amber 0.3–0.6, Red <0.3.
No citation freshness data yet. Export bibliography — run scripts/audit_citation_freshness.py to populate.
Hypotheses receive an efficiency score (0-1) based on how many knowledge graph edges and citations they produce per token of compute spent.
High-efficiency hypotheses (score >= 0.8) get a price premium in the market, pulling their price toward $0.580.
Low-efficiency hypotheses (score < 0.6) receive a discount, pulling their price toward $0.420.
Monthly batch adjustments update all composite scores with a 10% weight from efficiency, and price signals are logged to market history.
Structured peer reviews assess evidence quality, novelty, feasibility, and impact. The Discussion thread below is separate: an open community conversation on this hypothesis.
No DepMap CRISPR Chronos data found for NMJ.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No governance decisions recorded for this hypothesis.
Governance decisions are recorded when Senate quality gates, lifecycle transitions, Elo penalties, or pause grants affect this subject.
No knowledge graph edges recorded
neurodegeneration | 2026-04-27 | open
No comments yet. Be the first to comment!